AUTOLUS THERAPEUTICS PLC Stock Price, News & Analysis

Autolus Therapeutics (AUTL) reported its Q3 2020 financial results, highlighting operational progress in clinical trials for AUTO3 and AUTO1 programs. The company presented promising data at the ESMO 2020, showing favorable outcomes for AUTO3 in DLBCL. As of September 30, 2020, cash and equivalents totaled $177.7 million, down from $212.0 million at June 30, 2020. Operating expenses increased to $42.7 million, with R&D expenses rising to $33.5 million from $27.3 million a year earlier. The net loss attributable to shareholders was $37.3 million, compared to $27.2 million in 2019.

Autolus Therapeutics plc (Nasdaq: AUTL) announced its upcoming third quarter 2020 financial results and operational highlights, which will be released before U.S. market opening on November 5, 2020. Management will conduct a conference call at 8:30 AM ET to discuss these results and provide a business update. Interested parties can access the webcast through the company's investor relations page. Details for accessing the call are also provided for both domestic and international callers, along with information for replay after the event.

Autolus Therapeutics (AUTL) announced significant progress on AUTO3, a dual-targeting CAR T cell therapy for diffuse large B cell lymphoma, during the ESMO Virtual Congress 2020. New data from the Phase 1/2 ALEXANDER study reveal a promising 64% complete response rate and a 71% overall response rate in evaluated patients. AUTO3 demonstrated a favorable safety profile, with low rates of neurotoxicity and no serious cytokine release syndrome reported. The results position AUTO3 as a potential best-in-class treatment option, highlighting its durability and efficacy in a patient cohort.

Autolus Therapeutics plc (Nasdaq: AUTL) has announced an upcoming investor conference call to discuss data on its AUTO3 program presented at the ESMO Virtual Congress 2020. Key events include participation in the Wells Fargo Virtual Healthcare Conference on September 9, the H.C. Wainwright & Co conference on September 15, and the Cantor Fitzgerald conference on September 17. A detailed investor call regarding AUTO3 will occur on September 18, with Dr. Christian Itin and the clinical team. For additional details, visit Autolus.

Autolus Therapeutics (NASDAQ: AUTL) announced the initiation of its pivotal Phase 1b/2 AUTO1-AL1 study for adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL). As of May 13, 2020, AUTO1 demonstrated a favorable safety profile, achieving an 84% MRD-negative complete response (CR) in 19 patients. Notably, event-free survival at 6 months was 62%, with overall survival at 72%. Meanwhile, progress on AUTO3 suggests potential use in outpatient settings. The company will discuss EHA data in a conference call on June 12, 2020.

Autolus Therapeutics plc (Nasdaq: AUTL) has rescheduled its investor conference call to discuss data from the European Hematology Association EHA25 Virtual Congress to June 12, 2020, at 7:30 am EDT. Previously set for June 15, the call will feature Dr. Christian Itin and the AUTO1 and AUTO3 clinical teams discussing CAR T cell therapies targeting adult Acute Lymphocytic Leukemia and relapsed/refractory Diffuse Large B Cell Lymphoma. Investors can join via a dial-in or webcast, with a replay available afterward.

Autolus Therapeutics (AUTL) has announced its Annual General Meeting (AGM) scheduled for June 18, 2020, at its headquarters in White City. Due to UK government Stay at Home Measures amid the coronavirus pandemic, only two shareholders will attend in person, and the meeting will not have a webcast. Shareholders are urged to vote via proxy ahead of the meeting, as in-person voting is not permitted this year. Results of the poll votes will be communicated through a subsequent press release. Autolus focuses on developing innovative programmed T cell therapies for cancer treatment.

Autolus Therapeutics plc (Nasdaq: AUTL) announced new preclinical data on its programmed T cell therapies at the AACR Virtual Annual Meeting II, scheduled for June 22-24, 2020. Key presentations include AUTO5 targeting T cell lymphoma, AUTO6NG for small cell lung cancer, and AUTO7 for advanced prostate cancer. Oral and poster presentations will showcase the advancements and efficacy of these therapies. A conference call to discuss the findings will be held on June 25, 2020, at 8:30 am EDT. These developments highlight Autolus's commitment to innovative cancer treatments.